Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16456006 | 0.85 | PKM (0.46) | TNKSMAPK1CDK5CDK5R1BRD4 | |
| SCHEMBL6657476 | 0.72 | MAPK1 (0.52) | TNKSMAPK1HTR5ACTSS | |
| SCHEMBL21966127 | 0.70 | HTR2C (0.43) | MAPK1 | |
| SCHEMBL17803177 | 0.70 | BRD4 (0.52) | TNKSMAPK1BRD4CTSS | |
| SCHEMBL2872824 | 0.70 | BRD4 (0.56) | BRD4CTSS | |
| SCHEMBL434040 | 0.70 | BRD4 (0.68) | CDK5CDK5R1BRD4 | |
| SCHEMBL16456393 | 0.68 | TNKS (0.61) | TNKSMAPK1BRD4 | |
| SCHEMBL18218827 | 0.67 | HTR2A (0.52) | MAPK1GRIA2 | |
| SCHEMBL3603875 | 0.67 | BRD4 (0.55) | TNKSMAPK1BRD4CTSS | |
| SCHEMBL5378326 | 0.67 | MAPK1 (0.49) | TNKSMAPK1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | TNKS 2/4885MAPK1 1337/4885OPRM1 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.